It was a pleasure to hear from David Leppert (University Hospital Basel and University of Basel, Basel, Switzerland) on his late-breaking presentation about the exciting potential of neutrophil granulocyte markers in the cerebrospinal fluid to differentiate neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) from multiple sclerosis (MS) in the acute disease phase.
Questions
- Briefly, what are the clinical and pathological similarities between neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody disease (MOGAD) and multiple sclerosis (MS)? (0:06)
- What methods have been used in the past to distinguish these conditions and what are the limitations of these methods? (2:16)
- Could you give us an overview of the rationale for and design of your study investigating neutrophil granulocyte markers in cerebrospinal fluid? (3:38)
- What were the major findings of your study? (6:11)
- What is the potential impact of these findings on clinical practice and what future studies are planned? (7:16)
Disclosures: David Leppert has been Therapeutic Area Head at Novartis, Neuroscience Development Unit, until January 2019. He is Senior Research Associate at the Department of Neurology at University Hospitals Basel, and Chief Medical Officer of GeNeuro. He has received personal compensation for consulting and speaking, and travel reimbursement from Quanterix, Orion, Novartis, Roche and Sanofi.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020.
